Prot #NU 12H09: A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas

  • Pro, Barbara (PD/PI)
  • Kaplan, Jason B (Other)

Project: Research project

Project Details

StatusFinished
Effective start/end date2/26/13 → 2/26/23

Funding

  • Seattle Genetics, Inc. ((OE) Prot# NU 12H09)